Home > Riviste > Minerva Endocrinology > Fascicoli precedenti > Articles online first > Minerva Endocrinology 2022 Feb 23

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Endocrinology 2022 Feb 23

DOI: 10.23736/S2724-6507.21.03336-4

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Anandamide is associated with waist-to-hip ratio but not with body mass index in women with polycystic ovary syndrome

Plamena KABAKCHIEVA 1, 2 , Antoaneta GATEVA 1, Tsvetelina VELIKOVA 3, Tsvetoslav GEORGIEV 4, Zdravko KAMENOV 1

1 Department of Internal Medicine, Clinic of Endocrinology, University Hospital Alexandrovska, Medical Faculty, Medical University of Sofia, Sofia, Bulgaria; 2 Clinic of Internal Diseases, Naval Hospital - Varna, Military Medical Academy, Bulgaria; 3 Laboratory of Clinical Immunology, Medical Faculty, University Hospital Lozenetz, Sofia University St. Kliment Ohridski, Sofia, Bulgaria; 4 First Department of Internal Medicine, Medical Faculty, University Hospital St. Marina, Medical University - Varna, Varna, Bulgaria


PDF


BACKGROUND: The endocannabinoid system is involved in the regulation of energy balance and ovarian function and may be implicated in the pathogenesis of polycystic ovary syndrome (PCOS). The purpose of the present study is to determine anandamide (AEA) levels in PCOS patients and controls and to analyze its association with metabolic and hormonal disturbances in women with PCOS.
METHODS: The study included 88 women - 58 patients with PCOS (25.9±5.2 years) and 30 healthy controls (27.6±5.2 years). Further, patients were divided into two subgroups according to their waist-to-hip ratio (WHR): android type PCOS (WHR≥0.85; n=26) and gynoid type PCOS (WHR<0.85; n=32). Detailed anthropometric measurements, hormonal and biochemical tests and pelvic ultrasound were obtained between the 3rd and 5th day of a menstrual cycle. AEA was examined by ELISA kits.
RESULTS: Patients with PCOS and healthy controls did not differ in anthropometric, metabolic parameters, AEA, and sex hormone-binding globulin (SHBG) levels. The PCOS group had increased total testosterone, FAI, DHEAS, androstenedione, and 17-OHprogesterone levels (p<0.001) and elevated LH/FSH ratio (p=0.023). A negative correlation between AEA levels was found with glycaemia at 120 minutes (r=-0.304, p=0.020) and WHR (r=-0.266, p=0.044). In the subanalysis of patients, the gynoid type group had significantly higher levels of AEA than the android type PCOS (5.4 [2.3;8.8] vs. 2.5 [1.8;5.1]; p=0.020).
CONCLUSIONS: AEA did not differ between healthy women and patients, but a significant difference in its levels was found in PCOS patients divided according to their body constitution type.


KEY WORDS: Polycystic ovary syndrome; Endocannabinoids; Waist-hip ratio; Body fat distribution; Body mass index

inizio pagina